Role of abetimus in systemic lupus erythematosus
Future Rheumatology · 2006
DOI: 10.2217/17460816.1.2.167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Rheumatology, 2006. Verfasst von Manuja Joshi und 1 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
Anti-DNA antibodies and the B cells that produce them play a major pathogenic role in lupus nephritis. Although current immunosuppressive therapy suppresses autoantibody production and B-cell activity, it is often associated with severe side effects. Abetimus, a soluble, synthetic, double-stranded (ds)DNA tetramer, was developed to bind to circulating DNA antibodies and membrane-bound anti-DNA antibodies on B cells, with the goal of removing circulating pathogenic antibodies and inducing B-cell tolerance. Two large clinical trials with this agent have shown promising results in reducing lupus nephritis flares, especially in patients with high affinity anti-dsDNA antibodies. Nevertheless, although safe and well tolerated, the second trial did not reproduce the desired, statistically significant end point. This was probably due to the trial design and, therefore, given its potential efficacy and safety profile, it seems that once dosing is optimized and the responsive patient population is defined, abetimus...
Zitieren
APA
Joshi, M., & Madaio, M. P. (2006). Role of abetimus in systemic lupus erythematosus. Future Rheumatology. https://doi.org/10.2217/17460816.1.2.167
Vancouver
Joshi M, Madaio MP. Role of abetimus in systemic lupus erythematosus. Future Rheumatology. 2006. doi:10.2217/17460816.1.2.167
BibTeX
@article{Joshi2006,
author = {Joshi, Manuja and Madaio, Michael P},
title = {Role of abetimus in systemic lupus erythematosus},
journal = {Future Rheumatology},
year = {2006},
doi = {10.2217/17460816.1.2.167}
}
EUVIMED